<?xml version='1.0' encoding='utf-8'?>
<document id="25972738"><sentence text="The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits."><entity charOffset="14-26" id="DDI-PubMed.25972738.s1.e0" text="pioglitazone" /><entity charOffset="50-63" id="DDI-PubMed.25972738.s1.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.25972738.s1.e0" e2="DDI-PubMed.25972738.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25972738.s1.e0" e2="DDI-PubMed.25972738.s1.e1" /></sentence><sentence text="Drug-drug interactions can lead to serious and potentially lethal adverse events" /><sentence text=" In recent years, several drugs have been withdrawn from the market due to interaction-related adverse events" /><sentence text=" The objective of this study was to evaluate the pharmacokinetic interaction between pioglitazone (PG) and carbamazepine (CBZ) in healthy male rabbits"><entity charOffset="85-97" id="DDI-PubMed.25972738.s4.e0" text="pioglitazone" /><entity charOffset="99-101" id="DDI-PubMed.25972738.s4.e1" text="PG" /><entity charOffset="107-120" id="DDI-PubMed.25972738.s4.e2" text="carbamazepine" /><entity charOffset="122-125" id="DDI-PubMed.25972738.s4.e3" text="CBZ" /><pair ddi="false" e1="DDI-PubMed.25972738.s4.e0" e2="DDI-PubMed.25972738.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25972738.s4.e0" e2="DDI-PubMed.25972738.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25972738.s4.e0" e2="DDI-PubMed.25972738.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25972738.s4.e0" e2="DDI-PubMed.25972738.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25972738.s4.e1" e2="DDI-PubMed.25972738.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25972738.s4.e1" e2="DDI-PubMed.25972738.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25972738.s4.e1" e2="DDI-PubMed.25972738.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25972738.s4.e2" e2="DDI-PubMed.25972738.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25972738.s4.e2" e2="DDI-PubMed.25972738.s4.e3" /></sentence><sentence text="" /><sentence text="A randomized, two-crossover design study was conducted in six healthy male rabbits" /><sentence text=" The study consisted of two periods: period one, when each rabbit received a single dose of 70 mg CBZ-suspension"><entity charOffset="98-100" id="DDI-PubMed.25972738.s7.e0" text="CBZ" /></sentence><sentence text=" Period two, when each rabbit received a single dose of 70 mg CBZ-suspension co-administered with a single dose of 1"><entity charOffset="62-64" id="DDI-PubMed.25972738.s8.e0" text="CBZ" /></sentence><sentence text="5 mg PG with a washout period of one week between the two periods"><entity charOffset="5-7" id="DDI-PubMed.25972738.s9.e0" text="PG" /></sentence><sentence text=" Serial blood samples were collected over a period of 48 h" /><sentence text=" Chemiluminescent enzyme immunoassay (CLEIA) was used to measure CBZ in serum"><entity charOffset="65-66" id="DDI-PubMed.25972738.s11.e0" text="CBZ" /></sentence><sentence text=" Pharmacokinetic (PK) parameters Cmax, Tmax, t 1/2, AUC0-t, AUC 0-∞, and ke were determined for the two periods using non-compartmental analysis" /><sentence text="" /><sentence text="In the two periods of treatment, Cmax, Tmax, AUC0-t, AUC0-∞, t ½ and ke for CBZ were administered alone and in combination with PG"><entity charOffset="128-130" id="DDI-PubMed.25972738.s14.e0" text="PG" /><entity charOffset="76-78" id="DDI-PubMed.25972738.s14.e1" text="CBZ" /><pair ddi="false" e1="DDI-PubMed.25972738.s14.e1" e2="DDI-PubMed.25972738.s14.e1" /><pair ddi="false" e1="DDI-PubMed.25972738.s14.e1" e2="DDI-PubMed.25972738.s14.e0" /></sentence><sentence text=" Cmax, the mean peak plasma concentration was 4" /><sentence text="33 ± 2" /><sentence text="4 μg/mL versus 4" /><sentence text="76 ± 2" /><sentence text="1 μg/ml, tmax, time taken to reach, was 2" /><sentence text="91 ± 1" /><sentence text="11 h versus 3" /><sentence text="6 ± 1" /><sentence text="83 h, total area under the curve AUC0-t was 64" /><sentence text="90 ± 43" /><sentence text="6 μg·h/ml versus 102" /><sentence text="90 ± 66" /><sentence text="9 μg·h/ml, AUC0-∞ was 74" /><sentence text="0 ± 52" /><sentence text="6 μg·h/ml versus 124" /><sentence text="3 ± 85 μg·h/mL, t ½ was 14" /><sentence text="10 ± 2" /><sentence text="5 h versus 16" /><sentence text="43 ± 6" /><sentence text="43 h and elimination rate constant ke was 0" /><sentence text="050 ± 0" /><sentence text="009 h(-1) versus 0" /><sentence text="057 ± 0" /><sentence text="049 h(-1), respectively" /><sentence text=" No statistical differences were found in pharmacokinetic of CBZ in both cases (P &gt; 0"><entity charOffset="61-63" id="DDI-PubMed.25972738.s39.e0" text="CBZ" /></sentence><sentence text="05)" /><sentence text="" /><sentence text="The result of the study demonstrated that PG does not affect pharmacokinetic parameters of CBZ"><entity charOffset="42-44" id="DDI-PubMed.25972738.s42.e0" text="PG" /><entity charOffset="91-93" id="DDI-PubMed.25972738.s42.e1" text="CBZ" /><pair ddi="false" e1="DDI-PubMed.25972738.s42.e0" e2="DDI-PubMed.25972738.s42.e0" /><pair ddi="false" e1="DDI-PubMed.25972738.s42.e0" e2="DDI-PubMed.25972738.s42.e1" /></sentence><sentence text=" Therefore, no cautions regarding dose or administration pattern of CBZ with PG should be taken"><entity charOffset="77-79" id="DDI-PubMed.25972738.s43.e0" text="PG" /><entity charOffset="68-70" id="DDI-PubMed.25972738.s43.e1" text="CBZ" /><pair ddi="false" e1="DDI-PubMed.25972738.s43.e1" e2="DDI-PubMed.25972738.s43.e1" /><pair ddi="false" e1="DDI-PubMed.25972738.s43.e1" e2="DDI-PubMed.25972738.s43.e0" /></sentence><sentence text="" /></document>